The role of mutant UDP-N-acetyl-α-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 10, 2006, Pages 4037-4042

  Garringer, Holly J ^a   Fisher, Corinne ^b   Larsson, Tobias E ^a   Davis, Siobhan I ^a   Koller, Daniel L ^a   Cullen, Michael J ^c   Draman, Mohamad S ^c   Conlon, Niamh ^c   Jain, Alka ^d   Fedarko, Neal S ^d   Dasgupta, Bhaskar ^b   White, Kenneth E ^a,e  

^a INDIANA UNIVERSITY   (United States)

^b SOUTHEND UNIVERSITY HOSPITAL   (United Kingdom)

^c ST JAMES S HOSPITAL   (Ireland)

^d JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^e IB130 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; FIBROBLAST GROWTH FACTOR 23; N ACETYL D GALACTOSAMINE POLYPEPTIDE N ACETYLGALACTOSAMINYTRANSFERASE 3; SEVELAMER; UNCLASSIFIED DRUG;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CLINICAL ASSESSMENT; CONTROLLED STUDY; EXON; FAMILIAL DISEASE; GALNT3 GENE; GENE; GENE DELETION; HOMEOSTASIS; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; PATIENT ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; TUMOR CALCINOSIS;

EID: 33749576547     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-0305     Document Type: Article

References (24)

1. Topaz O, Shurman DL, Bergman R, Indelman M, Ratajczak P, Mizrachi M, Khamaysi Z, Behar D, Petronius D, Friedman V, Zelikovic I, Raimer S, Metzker A, Richard G, Sprecher E 2004 Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 36:579-581
2. Bennett EP, Hassan H, Clausen H 1996 cDNA cloning and expression of a novel human UDP-N-acetyl-alpha-d-galactosamine. Polypeptide N- acetylgalactosaminyltransferase, GalNAc-T3. J Biol Chem 271:17006-17012
3. Larsson T, Yu X, Davis SI, Draman MS, Mooney SD, Cullen MJ, White KE 2005 A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab 90:2424-2427
4. Araya K, Fukumoto S, Backenroth R, Takeuchi Y, Nakayama K, Ito N, Yoshii N, Yamazaki Y, Yamashita T, Silver J, Igarashi T, Fujita T 2005 A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab 90:5523-5527
5. Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B 2005 An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 14:385-390
6. Larsson T, Davis SI, Garringer HJ, Mooney SD, Draman MS, Cullen MJ, White KE 2005 Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed. Endocrinology 146:3883-3891
7. ADHR Consortium 2000 Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345-348
8. Econs MJ, McEnery PT 1997 Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 82:674-681
9. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ 2001 Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079-2086
10. Rowe PS, de Zoysa PA, Dong R, Wang HR, White KE, Econs MJ, Oudet CL 2000 MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 67:54-68
11. Bresler D, Bruder J, Mohnike K, Fraser WD, Rowe PS 2004 Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets. J Endocrinol 183:R1-R9
12. Rowe PS, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, Rosen D, Cundy J, Navvab S, Chen D, Drezner MK, Quarles LD, Mundy GR 2004 MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34:303-319
13. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2001 Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500-6505
14. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S 2002 Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957-4960
15. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H 2003 Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656-1663
16. Jain A, Fedarko NS, Collins MT, Gelman R, Ankrom MA, Tayback M, Fisher LW 2004 Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density. J Clin Endocrinol Metab 89:4158-4161
17. Specktor P, Cooper JG, Indelman M, Sprecher E 2006 Hyperphosphatemic familial tumoral calcinosis caused by a mutation in GALNT3 in a European kindred. J Hum Genet 51:487-490
18. Ichikawa S, Lyles KW, Econs MJ 2005 A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive. J Clin Endocrinol Metab 90:2420-2423
19. Campagnoli MF, Pucci A, Garelli E, Carando A, Defilippi C, Lala R, Ingrosso G, Dianzani I, Forni M, Ramenghi U 2006 Familial tumoral calcinosis and testicular microlithiasis associated with a new mutation of GALNT3 in a white family. J Clin Pathol 59:440-442
20. Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2002 Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143:3179-3182
21. Tezelman S, Siperstein AE, Duh QY, Clark OH 1993 Tumoral calcinosis. Controversies in the etiology and alternatives in the treatment. Arch Surg 128:737-744
22. Lufkin EG, Wilson DM, Smith LH, Bill NJ, DeLuca HF, Dousa TP, Knox FG 1980 Phosphorus excretion in tumoral calcinosis: response to parathyroid hormone and acetazolamide. J Clin Endocrinol Metab 50:648-653
23. Knox FG, Haas JA, Lechene CP 1976 Effect of parathyroid hormone on phosphate reabsorption in the presence of acetazolamide. Kidney Int 10:216-220
24. Mozaffarian G, Lafferty FW, Pearson OH 1972 Treatment of tumoral calcinosis with phosphorus deprivation. Ann Intern Med 77:741-745